ChaRactErization of patients following aCute venous thrOmboembolism (VTE) and assessment of safety and effectiveness of dabigatran etexilate (DE) in the tReatment and secondarY prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in comparison to vitamin K antagonist (VKA) in routine clinical practice - RE-COVERY DVT/PE

drug protocol number
1160.188
drug sponsor
Boehringer Ingelheim
drug study
Dabigatran etexilate
drug trial site
King Salman Bin AbdulAziz Hospital
drug status
Ongoing
drug phase